Loading…
The first Japanese biobank of patient‐derived pediatric acute lymphoblastic leukemia xenograft models
A lack of practical resources in Japan has limited preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL), which has poor outcomes. Here, we established 57 patient‐derived xenografts (PDXs) in NOD.Cg‐Prkdcscidll2rgtm1Sug/ShiJic (NOG) m...
Saved in:
Published in: | Cancer science 2022-11, Vol.113 (11), p.3814-3825 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | A lack of practical resources in Japan has limited preclinical discovery and testing of therapies for pediatric relapsed and refractory acute lymphoblastic leukemia (ALL), which has poor outcomes. Here, we established 57 patient‐derived xenografts (PDXs) in NOD.Cg‐Prkdcscidll2rgtm1Sug/ShiJic (NOG) mice and created a biobank by preserving PDX cells including three extramedullary relapsed ALL PDXs. We demonstrated that our PDX mice and PDX cells mimicked the biological features of relapsed ALL and that PDX models reproduced treatment‐mediated clonal selection. Our PDX biobank is a useful scientific resource for capturing drug sensitivity features of pediatric patients with ALL, providing an essential tool for the development of targeted therapies.
We established the first Japanese biobank of ALL‐PDX. With confirming the preservation of the characteristics of primary samples and the reproduction of treatment‐induced clonal selection in PDX model, this biobank will contribute to the acceleration of the applications of PDX model for preclinical research. |
---|---|
ISSN: | 1347-9032 1349-7006 |
DOI: | 10.1111/cas.15506 |